Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification
Open Access
- 1 December 2008
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (12) , 3880-3891
- https://doi.org/10.1128/jcm.00755-08
Abstract
Hepatitis C virus (HCV) RNA detection and quantification are the key diagnostic tools for the management of hepatitis C. Commercially available HCV RNA assays are calibrated to the HCV genotype 1 (gt1)-based WHO standard. Significant differences between assays have been reported. However, it is unknown which assay matches the WHO standard best, and little is known about the sensitivity and linear quantification of the assays for non-gt1 specimens. Two real-time reverse transcriptase PCR-based assays (RealTime HCV and Cobas Ampliprep/Cobas TaqMan HCV [CAP/CTM]) and one signal amplification-based assay (the Versant HCV RNA, version 3.0, branched DNA [bDNA] assay) were compared for their abilities to quantify HCV RNA in clinical specimens (n = 65) harboring HCV isolates of gt1 to g5. The mean differences in the amounts detected by RealTime HCV in comparison to those detected by the bDNA assay and CAP/CTM were −0.02 and 0.72 log10 IU/ml HCV RNA, respectively, for gt1; −0.22 and 0.03 log10 IU/ml HCV RNA, respectively, for gt2; −0.27 and −0.22 log10 IU/ml HCV RNA, respectively, for gt3; −0.19 and −1.27 log10 IU/ml HCV RNA, respectively, for gt4; and −0.03 and 0.09 log10 IU/ml HCV RNA, respectively, for gt5. The lower limits of detection for RealTime HCV and CAP/CTM were 16.8 and 10.3 IU/ml, respectively, for the WHO standard and in the range of 4.7 to 9.0 and 3.4 to 44.4 IU/ml, respectively, for clinical specimens harboring gt1 to gt6. Direct comparison of the two assays with samples of the WHO standard (code 96/798) with high titers yielded slightly smaller amounts by RealTime HCV (−0.2 log10 at 1,500 IU/ml and −0.3 log10 at 25,000 IU/ml) and larger amounts by CAP/CTM (0.3 log10 at 1,500 IU/ml and 0.2 log10 at 25,000 IU/ml). Finally, all three tests were linear between 4.0 × 103 and 1.0 × 106 IU/ml (correlation coefficient, ≥0.99). In conclusion, the real-time PCR based assays sensitively detected all genotypes and showed comparable linearities for the quantification of HCV RNA, with the exception of gt1 and gt4. The previously reported differences in the absolute quantification of samples harboring gt1 were confirmed and may be explained by different calibrations to the WHO standard.Keywords
This publication has 29 references indexed in Scilit:
- Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite StudyJournal of Clinical Microbiology, 2007
- Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA AssayJournal of Clinical Microbiology, 2007
- Evaluation of a New-Generation Line-Probe Assay That Detects 5' Untranslated and Core Regions to Genotype and Subtype Hepatitis C VirusAmerican Journal of Clinical Pathology, 2007
- Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV AssayJournal of Clinical Microbiology, 2007
- Real-Time PCR Assays for Hepatitis C Virus (HCV) RNA Quantitation Are Adequate for Clinical Management of Patients with Chronic HCV InfectionJournal of Clinical Microbiology, 2006
- Multilaboratory Comparison of Hepatitis C Virus Viral Load AssaysJournal of Clinical Microbiology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis CJournal of Hepatology, 2005
- World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assaysVox Sanguinis, 2005
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986